Enanta Pharmaceuticals Revenue 2011-2026 | ENTA

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Enanta Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
65.3 M	67.6 M	79.2 M	86.2 M	97.1 M	122 M	205 M	207 M	103 M	88.3 M	161 M	47.7 M	32.1 M	41.7 M	41.9 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
207 M	32.1 M	96.3 M

Quarterly Revenue Enanta Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
18.3 M	14.9 M	17 M	-	18 M	17.1 M	18 M	-	18.9 M	17.8 M	23.6 M	65.8 M	19.5 M	18.7 M	27.6 M	73.5 M	21.6 M	20.1 M	31.7 M	23.6 M	18.7 M	31.7 M	52.6 M	51.3 M	44.4 M	52.6 M	69.9 M	67.2 M	57.3 M	44 M	38.1 M	75.9 M	7.51 M	8.96 M	10.4 M	12.8 M	14 M	10.4 M	48.4 M	14.4 M	11.6 M	48.4 M	77.5 M	2.64 M	42.1 M	77.5 M	893 K	1.35 M	1.65 M	893 K	27.9 M	1.86 M	2.54 M	36.6 M	741 K	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
77.5 M	741 K	28.9 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	10.2 M	$ 1.65	7.91 %	$ 92.9 M	China
AstraZeneca PLC AZN	54.1 B	$ 93.52	-1.2 %	$ 96.9 B	Britain
Autolus Therapeutics plc AUTL	242 K	$ 1.52	-16.3 %	$ 388 M	Britain
Alterity Therapeutics Limited ATHE	109 K	$ 3.59	1.99 %	$ 8.64 B	Australia
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Biogen BIIB	9.68 B	$ 184.48	-1.67 %	$ 26.9 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
BioNTech SE BNTX	482 M	$ 102.17	2.32 %	$ 27.2 B	Germany
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Can-Fite BioPharma Ltd. CANF	853 K	$ 4.25	1.67 %	$ 9.25 B	Israel
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Ascendis Pharma A/S ASND	364 M	$ 207.49	2.22 %	$ 5 B	Danmark
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Catalyst Biosciences CBIO	113 M	$ 10.84	0.46 %	$ 714 M	USA
Adaptimmune Therapeutics plc ADAP	60.3 M	-	-15.15 %	$ 60.3 M	Britain
Corcept Therapeutics Incorporated CORT	675 M	$ 37.35	-0.4 %	$ 3.86 B	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Catalyst Pharmaceuticals CPRX	492 M	$ 23.18	2.02 %	$ 2.75 B	USA
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Celldex Therapeutics CLDX	7.02 M	$ 25.59	-6.54 %	$ 1.65 M	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Cellectis S.A. CLLS	41.5 M	$ 4.22	-4.2 %	$ 116 M	France
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	732 M	$ 29.43	6.09 %	$ 1.43 B	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	8.01 M	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	330 M	$ 9.66	2.28 %	$ 1.53 B	Britain
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	54 K	-	-6.81 %	$ 3.04 B	USA
Arrowhead Pharmaceuticals ARWR	829 M	$ 66.05	2.3 %	$ 8.83 B	USA
Athersys ATHX	5.51 M	-	3.77 %	$ 22.4 M	USA
Crinetics Pharmaceuticals CRNX	1.04 M	$ 55.11	3.49 %	$ 4.45 B	USA
Abeona Therapeutics ABEO	3.5 M	$ 5.14	-1.06 %	$ 110 M	USA
CRISPR Therapeutics AG CRSP	37.3 M	$ 55.17	2.47 %	$ 4.65 B	Schweiz
Axon Enterprise AXON	2.08 B	$ 632.29	0.09 %	$ 47.9 B	USA
ADiTx Therapeutics ADTX	134 K	$ 0.81	1.96 %	$ 10.7 K	USA
Aytu BioScience AYTU	66.4 M	$ 2.7	2.27 %	$ 17 M	USA